Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Jun 12, 2015
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The subject must be a patient at the Hospital of the University of Pennsylvania
- • The subject must be under evaluation and/or treatment for a pancreatic disease
- • The subject must be under evaluation and/or treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.
- • 2. The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf
- • 3. The subject must be 18 years of age or older
- Exclusion Criteria:
- • 1. The subject or acceptable surrogate does not provide informed consent
- • 2. Subject is a prisoner
- • 3. Subject is under 18 years of age
About Abramson Cancer Center At Penn Medicine
The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Peter O'Dwyer, MD
Principal Investigator
Abramson Cancer Center at Penn Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials